Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 6NIH 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Burkitt Lymphoma 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Rectal Neoplasms 3Pancreatic Neoplasms 3Colonic Neoplasms 3Carcinoma, Hepatocellular 3Salivary Gland Neoplasms 2Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Multiple Myeloma 2Melanoma 2Lymphoma 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Waldenstrom Macroglobulinemia 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Tongue Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sezary Syndrome 1Sarcoma 1

Interventions

Gemcitabine 54Specimen Handling 16Fluorouracil 15Radiotherapy 13Biopsy 12Oxaliplatin 10Magnetic Resonance Spectroscopy 10Erlotinib Hydrochloride 10Cyclophosphamide 10aldesleukin 8fludarabine 7Bevacizumab 7sargramostim 6Radiation 6veliparib 5Trastuzumab 5Leucovorin 5Cetuximab 5Capecitabine 5Taxes 4Sunitinib 4Irinotecan 4HhAntag691 4Cisplatin 42,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 4tipifarnib 3rubitecan 3entinostat 3X-Rays 3Sorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Pancreatic Neoplasms × Dasatinib × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT01660971 2026-04-13

Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Active not recruiting
19 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00474812 2015-05-05

Dasatinib in Treating Patients With Metastatic Pancreatic Cancer

National Cancer Institute (NCI)

Phase 2 Completed
51 enrolled 10 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡